Enhabit (NYSE:EHAB) Issues Earnings Results

Enhabit (NYSE:EHAB) posted its quarterly earnings results on Wednesday. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.03), Zacks reports. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%.

Enhabit Stock Performance

Shares of NYSE:EHAB traded up $0.08 during trading on Wednesday, hitting $8.55. The stock had a trading volume of 305,901 shares, compared to its average volume of 276,512. The stock has a 50-day simple moving average of $8.16 and a two-hundred day simple moving average of $7.90. The stock has a market capitalization of $430.13 million, a price-to-earnings ratio of -3.69 and a beta of 1.83. Enhabit has a 12-month low of $6.85 and a 12-month high of $11.74. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85.

Insider Buying and Selling

In related news, Director Jeffrey Bolton bought 4,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the purchase, the director now directly owns 98,144 shares of the company’s stock, valued at $852,871.36. This represents a 4.25 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stuart M. Mcguigan bought 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average cost of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the acquisition, the director now owns 46,810 shares of the company’s stock, valued at $412,396.10. This trade represents a 47.15 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EHAB. Jefferies Financial Group raised Enhabit from a “hold” rating to a “buy” rating and lifted their target price for the company from $8.25 to $9.50 in a research report on Monday, December 9th. Leerink Partners restated a “market perform” rating and set a $8.00 price target (down previously from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.75.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.